



XX  
 PT Nucleic acids encoding 2 human tumor necrosis factor receptor  
 PT polypeptides ((TRI3) and (R11)), useful for the prevention, diagnosis  
 and treatment of, e.g., cancers, neurodegenerative diseases, acquired immune deficiency syndrome and  
 XX  
 PS Claim 4: Page 394-398; 418pp; English.  
 The present invention provides the protein and coding sequences of the  
 human tumour necrosis factor receptors TRI3 and R11. These sequences are  
 useful in the diagnosis and treatment of many diseases, including cancer,  
 autoimmune diseases and neurodegenerative diseases, graft rejection, allergies,  
 inflammatory, aneurysms and infections.

Sequence 3334 BP; 820 A; 952 C; 811 G; 751 T; 0 other;  
 Best Local Similarity 100.0%; Score 3334; DB 22; Length 3334;

OY 1 GCAGAAAGAGAGCAGACCTTCGCGACAGACTGAGGGAGACTAGAGGCC 0;  
 Mismatches 0; Indels 0; Gaps 0;

Db 1 GCAGAAAGAGAGCAGACCTTCGCGACAGACTGAGGGAGACTAGAGGCC 0;  
 QY 61 GCTGAGCTTGCGCACACGACCACTTGAGCCCTACTCAGGACAACCTATG 60  
 Db 61 GCTGAGCTTGCGCACACGACCACTTGAGCCCTACTCAGGACAACCTATG 60  
 OY 121 ATAACCGCGCTGTGGCGGCTTACCGCTTCGCGACAGACTGAGGGGT 120  
 Db 121 ATAACCGCGCTGTGGCGGCTTACCGCTTCGCGACAGACTGAGGGGT 120  
 OY 181 AGGGACCGCAGGTTACGGCTGCAGCACCATCTCCGCGCACACGACCTATG 180  
 Db 181 AGGGACCGCAGGTTACGGCTGCAGCACCATCTCCGCGCACACGACCTATG 180  
 OY 301 CTGGCTGACCCCTCAAGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 300  
 Db 301 CTGGCTGACCCCTCAAGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 300  
 OY 361 GATGATGAGGACGACTCAGTCAAGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 360  
 Db 361 GATGATGAGGACGACTCAGTCAAGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 360  
 OY 421 ATTGGTGTGAGGACTGGGAGCTGCCCAGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 420  
 Db 421 ATTGGTGTGAGGACTGGGAGCTGCCCAGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 420  
 OY 481 GAGCTGAGTACGAGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 480  
 Db 481 GAGCTGAGTACGAGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 480  
 OY 541 CGGGCGGACTACAGCCTTCAGGAGACTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 540  
 Db 541 CGGGCGGACTACAGCCTTCAGGAGACTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 540  
 OY 601 AACCTGAGGAACTGGGACCTTACTCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 600  
 Db 601 AACCTGAGGAACTGGGACCTTACTCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 600  
 OY 661 TTGGATTTGGCTGAGAATGCTGAGGCTTACCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 660  
 Db 661 TTGGATTTGGCTGAGAATGCTGAGGCTTACCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 660  
 OY 721 AAGGACACAGAGAAGGAGTGGCACTGAGGCTTACCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 720  
 Db 721 AAGGACACAGAGAAGGAGTGGCACTGAGGCTTACCTGAGAATGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 720  
 OY 1801 ATGGCTCTGGCTCTACTCTGCGTCCCTGCGCTAGACGCTCTGAGTGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 1800  
 Db 1801 ATGGCTCTGGCTCTACTCTGCGTCCCTGCGCTAGACGCTCTGAGTGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 1800  
 OY 1861 TGCACCTCTGGCTCTACTCTGCGTCCCTGCGCTAGACGCTCTGAGTGGCTGAGGCTTACCGCTTCGCGACAGACTGAGGGGT 1860

Wed Mar 12 10:08:32 2003

PR 05-MAY-2000; 20000W0-US14042. 05-JUN-2000; 20000W0-US14911. 10-NOV-2000; 20000W0-US15264. PA (GETH ) GENENTECH INC.	
PT	Baker K.P., Beresini M., Deforge L., Desnoyers L., Filvaroff E., Gao W., Gerritten M., Goddard A., Godowski P., Gurney A.L., Sherwood S., Smith M., Stewart T.A., Tumas D., Watabane C.K., Wood M., Zhang Z;
PT	Isolated, secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, to modulate biological activities of cells expressing PRO polypeptides, to module biological molecules to cells expressing PRO polypeptides, to detect biological activities of cells expressing PRO polypeptides, rectal, cervical tumour necrosis factor, release of proinflammatory cytokines from skeletal muscle cells, modulate glucose or free fatty acid uptake by T-lymphocyte cells, the proliferation of chondrocytes, the release of monocytes (RAWCs), the release of inner ear proteoglycans from skeletal muscle cells, the proliferation of fibroblast-like cells or to factor VIIa, the proliferation of adipocytes; or inhibit binding of PRO polypeptides involved in binding interactions can be used to generate probes, antisense RNA/DNA, transgenic or knock out animals and can be used to identify
PT	PRO polypeptides, encode for novel human secretory and transmembrane PRO polypeptides, to link bioactive molecules to cells expressing PRO polypeptides, to module biological molecules to cells expressing PRO polypeptides, to detect biological activities of cells expressing PRO polypeptides, rectal, cervical tumour necrosis factor, release of proinflammatory cytokines from skeletal muscle cells, modulate glucose or free fatty acid uptake by T-lymphocyte cells, the proliferation of chondrocytes, the release of monocytes (RAWCs), the release of inner ear proteoglycans from skeletal muscle cells, the proliferation of fibroblast-like cells or to factor VIIa, the proliferation of adipocytes; or inhibit binding of PRO polypeptides involved in binding interactions can be used to generate probes, antisense RNA/DNA, transgenic or knock out animals and can be used to identify
CC	Query Match 3501: BP; 921 A; 979 C; 823 G; 776 T; 2 other; Best local Similarity 99.1%; Score 3303.4; Pred. No.: 0; Mismatches 3321; Conservative 0; Indels 1; Gaps 1; Matches 3321; Length 3501;
CC	1 GCAGAACGACGAGCGCACACCACTGAGCC 13; 2 ATGGAAAGCAGCACAGCGCACACTGAGCC 1; 3 ATGGAAAGCAGCACACCACTGAGCC 1; 4 ATGGAAAGCAGCACACCACTGAGCC 1; 5 ATGGAAAGCAGCACACCACTGAGCC 1; 6 ATGGAAAGCAGCACACCACTGAGCC 1; 7 ATGGAAAGCAGCACACCACTGAGCC 1; 8 ATGGAAAGCAGCACACCACTGAGCC 1; 9 ATGGAAAGCAGCACACCACTGAGCC 1; 10 ATGGAAAGCAGCACACCACTGAGCC 1; 11 ATGGAAAGCAGCACACCACTGAGCC 1; 12 ATGGAAAGCAGCACACCACTGAGCC 1; 13 ATGGAAAGCAGCACACCACTGAGCC 1; 14 ATGGAAAGCAGCACACCACTGAGCC 1; 15 ATGGAAAGCAGCACACCACTGAGCC 1; 16 ATGGAAAGCAGCACACCACTGAGCC 1; 17 ATGGAAAGCAGCACACCACTGAGCC 1; 18 ATGGAAAGCAGCACACCACTGAGCC 1; 19 ATGGAAAGCAGCACACCACTGAGCC 1; 20 ATGGAAAGCAGCACACCACTGAGCC 1; 21 ATGGAAAGCAGCACACCACTGAGCC 1; 22 ATGGAAAGCAGCACACCACTGAGCC 1; 23 ATGGAAAGCAGCACACCACTGAGCC 1; 24 ATGGAAAGCAGCACACCACTGAGCC 1; 25 ATGGAAAGCAGCACACCACTGAGCC 1; 26 ATGGAAAGCAGCACACCACTGAGCC 1; 27 ATGGAAAGCAGCACACCACTGAGCC 1; 28 ATGGAAAGCAGCACACCACTGAGCC 1; 29 ATGGAAAGCAGCACACCACTGAGCC 1; 30 ATGGAAAGCAGCACACCACTGAGCC 1; 31 ATGGAAAGCAGCACACCACTGAGCC 1; 32 ATGGAAAGCAGCACACCACTGAGCC 1; 33 ATGGAAAGCAGCACACCACTGAGCC 1; 34 ATGGAAAGCAGCACACCACTGAGCC 1; 35 ATGGAAAGCAGCACACCACTGAGCC 1; 36 ATGGAAAGCAGCACACCACTGAGCC 1; 37 ATGGAAAGCAGCACACCACTGAGCC 1; 38 ATGGAAAGCAGCACACCACTGAGCC 1; 39 ATGGAAAGCAGCACACCACTGAGCC 1; 40 ATGGAAAGCAGCACACCACTGAGCC 1; 41 ATGGAAAGCAGCACACCACTGAGCC 1; 42 ATGGAAAGCAGCACACCACTGAGCC 1; 43 ATGGAAAGCAGCACACCACTGAGCC 1; 44 ATGGAAAGCAGCACACCACTGAGCC 1; 45 ATGGAAAGCAGCACACCACTGAGCC 1; 46 ATGGAAAGCAGCACACCACTGAGCC 1; 47 ATGGAAAGCAGCACACCACTGAGCC 1; 48 ATGGAAAGCAGCACACCACTGAGCC 1; 49 ATGGAAAGCAGCACACCACTGAGCC 1; 50 ATGGAAAGCAGCACACCACTGAGCC 1; 51 ATGGAAAGCAGCACACCACTGAGCC 1; 52 ATGGAAAGCAGCACACCACTGAGCC 1; 53 ATGGAAAGCAGCACACCACTGAGCC 1; 54 ATGGAAAGCAGCACACCACTGAGCC 1; 55 ATGGAAAGCAGCACACCACTGAGCC 1; 56 ATGGAAAGCAGCACACCACTGAGCC 1; 57 ATGGAAAGCAGCACACCACTGAGCC 1; 58 ATGGAAAGCAGCACACCACTGAGCC 1; 59 ATGGAAAGCAGCACACCACTGAGCC 1; 60 ATGGAAAGCAGCACACCACTGAGCC 1; 61 ATGGAAAGCAGCACACCACTGAGCC 1; 62 ATGGAAAGCAGCACACCACTGAGCC 1; 63 ATGGAAAGCAGCACACCACTGAGCC 1; 64 ATGGAAAGCAGCACACCACTGAGCC 1; 65 ATGGAAAGCAGCACACCACTGAGCC 1; 66 ATGGAAAGCAGCACACCACTGAGCC 1; 67 ATGGAAAGCAGCACACCACTGAGCC 1; 68 ATGGAAAGCAGCACACCACTGAGCC 1; 69 ATGGAAAGCAGCACACCACTGAGCC 1; 70 ATGGAAAGCAGCACACCACTGAGCC 1; 71 ATGGAAAGCAGCACACCACTGAGCC 1; 72 ATGGAAAGCAGCACACCACTGAGCC 1; 73 ATGGAAAGCAGCACACCACTGAGCC 1; 74 ATGGAAAGCAGCACACCACTGAGCC 1; 75 ATGGAAAGCAGCACACCACTGAGCC 1; 76 ATGGAAAGCAGCACACCACTGAGCC 1; 77 ATGGAAAGCAGCACACCACTGAGCC 1; 78 ATGGAAAGCAGCACACCACTGAGCC 1; 79 ATGGAAAGCAGCACACCACTGAGCC 1; 80 ATGGAAAGCAGCACACCACTGAGCC 1; 81 ATGGAAAGCAGCACACCACTGAGCC 1; 82 ATGGAAAGCAGCACACCACTGAGCC 1; 83 ATGGAAAGCAGCACACCACTGAGCC 1; 84 ATGGAAAGCAGCACACCACTGAGCC 1; 85 ATGGAAAGCAGCACACCACTGAGCC 1; 86 ATGGAAAGCAGCACACCACTGAGCC 1; 87 ATGGAAAGCAGCACACCACTGAGCC 1; 88 ATGGAAAGCAGCACACCACTGAGCC 1; 89 ATGGAAAGCAGCACACCACTGAGCC 1; 90 ATGGAAAGCAGCACACCACTGAGCC 1; 91 ATGGAAAGCAGCACACCACTGAGCC 1; 92 ATGGAAAGCAGCACACCACTGAGCC 1; 93 ATGGAAAGCAGCACACCACTGAGCC 1; 94 ATGGAAAGCAGCACACCACTGAGCC 1; 95 ATGGAAAGCAGCACACCACTGAGCC 1; 96 ATGGAAAGCAGCACACCACTGAGCC 1; 97 ATGGAAAGCAGCACACCACTGAGCC 1; 98 ATGGAAAGCAGCACACCACTGAGCC 1; 99 ATGGAAAGCAGCACACCACTGAGCC 1; 100 ATGGAAAGCAGCACACCACTGAGCC 1; 101 ATGGAAAGCAGCACACCACTGAGCC 1; 102 ATGGAAAGCAGCACACCACTGAGCC 1; 103 ATGGAAAGCAGCACACCACTGAGCC 1; 104 ATGGAAAGCAGCACACCACTGAGCC 1; 105 ATGGAAAGCAGCACACCACTGAGCC 1; 106 ATGGAAAGCAGCACACCACTGAGCC 1; 107 ATGGAAAGCAGCACACCACTGAGCC 1; 108 ATGGAAAGCAGCACACCACTGAGCC 1; 109 ATGGAAAGCAGCACACCACTGAGCC 1; 110 ATGGAAAGCAGCACACCACTGAGCC 1; 111 ATGGAAAGCAGCACACCACTGAGCC 1; 112 ATGGAAAGCAGCACACCACTGAGCC 1; 113 ATGGAAAGCAGCACACCACTGAGCC 1; 114 ATGGAAAGCAGCACACCACTGAGCC 1; 115 ATGGAAAGCAGCACACCACTGAGCC 1; 116 ATGGAAAGCAGCACACCACTGAGCC 1; 117 ATGGAAAGCAGCACACCACTGAGCC 1; 118 ATGGAAAGCAGCACACCACTGAGCC 1; 119 ATGGAAAGCAGCACACCACTGAGCC 1; 120 ATGGAAAGCAGCACACCACTGAGCC 1; 121 ATGGAAAGCAGCACACCACTGAGCC 1; 122 ATGGAAAGCAGCACACCACTGAGCC 1; 123 ATGGAAAGCAGCACACCACTGAGCC 1; 124 ATGGAAAGCAGCACACCACTGAGCC 1; 125 ATGGAAAGCAGCACACCACTGAGCC 1; 126 ATGGAAAGCAGCACACCACTGAGCC 1; 127 ATGGAAAGCAGCACACCACTGAGCC 1; 128 ATGGAAAGCAGCACACCACTGAGCC 1; 129 ATGGAAAGCAGCACACCACTGAGCC 1; 130 ATGGAAAGCAGCACACCACTGAGCC 1; 131 ATGGAAAGCAGCACACCACTGAGCC 1; 132 ATGGAAAGCAGCACACCACTGAGCC 1; 133 ATGGAAAGCAGCACACCACTGAGCC 1; 134 ATGGAAAGCAGCACACCACTGAGCC 1; 135 ATGGAAAGCAGCACACCACTGAGCC 1; 136 ATGGAAAGCAGCACACCACTGAGCC 1; 137 ATGGAAAGCAGCACACCACTGAGCC 1; 138 ATGGAAAGCAGCACACCACTGAGCC 1; 139 ATGGAAAGCAGCACACCACTGAGCC 1; 140 ATGGAAAGCAGCACACCACTGAGCC 1; 141 ATGGAAAGCAGCACACCACTGAGCC 1; 142 ATGGAAAGCAGCACACCACTGAGCC 1; 143 ATGGAAAGCAGCACACCACTGAGCC 1; 144 ATGGAAAGCAGCACACCACTGAGCC 1; 145 ATGGAAAGCAGCACACCACTGAGCC 1; 146 ATGGAAAGCAGCACACCACTGAGCC 1; 147 ATGGAAAGCAGCACACCACTGAGCC 1; 148 ATGGAAAGCAGCACACCACTGAGCC 1; 149 ATGGAAAGCAGCACACCACTGAGCC 1; 150 ATGGAAAGCAGCACACCACTGAGCC 1;

us-10-046-433-39.rng

Wed Mar 12 10:08:32 2003



us-10-046-433-39.rng

Wed Mar 12 10:08:32 2003



Wed Mar 12 10:08:32 2003

Db	781	GTCAGAAGAACATTCGCAATTACCGGGTGGCCTAACCTCGAGATCTTCUCCNGCAAACT
Dy	898	GCGAGCTTGCGACAGACAGCGGGTCCCTTTCTTGCAAACCTTGTGCCCAGGCCAACCTT 840
Db	841	GCGACGTRIGGCAGACAGAGGGCTCTCTCTCTCTCTGCAACTTGTGCCCAGGCCAACCTT 957
Dy	958	TCTATAAAGGAAAGAACCTCTTCGCAACCGAGTGTACCTTGAAATAACTAGAGAAAGGA 900
Db	901	TCTATAAAGGAAAGAACCTCTTCGCAACCGAGTGTACCTTGAAATAACTAGAGAAAGGA 1017
Dy	1018	TCTTCCTCCGTAACGTCGCGCCAGCTTGACAGACAAGATTTTCTACACACAGC 1020
b	961	TCTTCCTCCGTAACGTCGCGCCAGCTTGACAGACAAGATTTTCTACACACAGC 1077
b	1078	GCTCGGATGCCAACCGAGAGACACTCATGTCAAATGGCCAGGCCAACCTGCGCCAGCCACCTT 960
b	1081	ACCCGACCTGGGGCAGCTGAGCTGAGCTGCGCCAGCCACATATGGT 1137
b	1138	ACGGAGACCTTGAGGGCAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1080
b	1141	CCCTGCAACCCAGGCTCTCCAAACAAACACACAGGCTCCGCGCCAGGCCAACCTGCGCCAGCCAAATCTGT 1197
b	1141	CCCTGCAACCCAGGCTCTCCAAACAAACACACAGGCTCCGCGCCAGGCCAACCTGCGCCAGCCAAATCTGT 1140
b	1258	TCCATCTCAATGGCAGACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1257
b	1261	TTTGATATACAAATGGGACAGACGCTGCGCCACACAGGACCTGCGCCAGCCACCTGCGCCATATGGT 1200
b	1201	CCCTACTTCATGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1317
b	1318	TTTGATATACAAATGGGACAGACGCTGCGCCACACAGGACCTGCGCCAGCCACCTGCGCCATATGGT 1317
b	1318	TTTGATATACAAATGGGACAGACGCTGCGCCACACAGGACCTGCGCCAGCCACCTGCGCCATATGGT 1377
b	1378	ATCAACTTGAGTACAGGGATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1320
b	1321	ATCAACTTGAGTACAGGGATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 137
b	1438	GCTGCCGAGCTGAGCACATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1380
b	1441	CCTCCGCACTCGGGTGTGAGACAGACAGGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1440
b	1558	TTTGAGACCTCTGTTCTGAGACTTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1500
b	1501	TTTGAGACCTCTGTTCTGAGACTTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1497
b	1501	TTTGAGACCTCTGTTCTGAGACTTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1617
b	1618	ACCAACACTCTGTGAGACAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1560
b	1561	ACCAACACTCTGTGAGACAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1677
b	1678	ATTTGAGGAGACACTTACCAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1620
b	1678	ATTTGAGGAGACACTTACCAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1797
b	221	ATTTGAGGAGACACTTACCAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1737
b	38	GCAAGCAAGAAGTACACCAATGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1857
b	81	GCAAGCAAGAAGTACACCAATGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1800
b	1	TCTCGACCTCTGTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1917
b	1	TCTCGACCTCTGTGAGCTGAGCTGAGCTGAGCTGAGCTGAGAACATCTGT 1660
b	8	TGCCCCCTAACACATTCTGAGAACCTGAGCTGAGCTGAGCTGAGAACATCTGT 1977



QY	Db	601 AACCTGAAGCAATCTGGCACCGTTAACTTGGATACTACTTCCAGACTCCAGCATC	420
QY	421 AACCTGAACCAATCTGGACCGTTAACTTGGATACTACTTCCAGACTCCAGCATC	660	661 TTGAGTTTTCCTCGAAATGAGCACCTGAGCTTCCAGAGAACCTTTCATGAGGA
Db	481 TTGAGTTTTCCTCGAAATGAGCACCTGAGCTTCCAGAGAACCTTTCATGAGGA	680	681 GAGGAGAACACTACCAAGCTGAGCTTCCAGAGAACCTTTCATGAGGA
Db	721 AGACCAAGAGAAAGATGGGAACTTCCAGAGAACCTTTCATGAGCTTCCAGAGAACCTTTCATGAGGA	540	721 AGACCAAGAGAAAGATGGGAACTTCCAGAGAACCTTTCATGAGCTTCCAGAGAACCTTTCATGAGGA
Db	541 AAGACCACAGAGAAAGATGGGAACTTCCAGAGAACCTTTCATGAGCTTCCAGAGAACCTTTCATGAGGA	780	541 AAGACCACAGAGAAAGATGGGAACTTCCAGAGAACCTTTCATGAGCTTCCAGAGAACCTTTCATGAGGA
QY	781 CTTTGTGAGGACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG	720	781 CTTTGTGAGGACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG
Db	601 CCTTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG	840	601 CCTTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG
Db	841 AGAACATGGCCATACAGGGTGCCCTACACTTCCAGAATGCTTCCCTGCAACCTGG	660	841 AGAACATGGCCATACAGGGTGCCCTACACTTCCAGAATGCTTCCCTGCAACCTGG
Db	661 AGAACATGGCCATACAGGGTGCCCTACACTTCCAGAATGCTTCCCTGCAACCTGG	900	661 AGAACATGGCCATACAGGGTGCCCTACACTTCCAGAATGCTTCCCTGCAACCTGG
Db	901 AGCTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG	720	901 AGCTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG
Db	721 AGCTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG	960	721 AGCTATGGAGAACACAGCCCTCTCAGTATGGACCAAGTAATCCANGCTTGCGGTG
Db	841 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATCA	780	841 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATCA
Db	961 ATTAAGAGAAACTCTTGCCACCACTGGAGCTGAGCCCTGACAARACTCAGAGAAGGANTC	1020	961 ATTAAGAGAAACTCTTGCCACCACTGGAGCTGAGCCCTGACAARACTCAGAGAAGGANTC
Db	781 ATTAAGAGAAACTCTTGCCACCACTGGAGCTGAGCCCTGACAARACTCAGAGAAGGANTC	720	781 ATTAAGAGAAACTCTTGCCACCACTGGAGCTGAGCCCTGACAARACTCAGAGAAGGANTC
Db	1021 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATGASC	840	1021 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATGASC
Db	841 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATGASC	960	841 TCTTCTGTAACTGGCCAGCTGCACTTCTGCAACTTGCACACTTGCACGACTTATGASC
Db	961 TCGATGCCACAGAGACACACTCAGTAACTGACAAATGGCCAAGCGAAATATTGASC	1020	961 TCGATGCCACAGAGACACACTCAGTAACTGACAAATGGCCAAGCGAAATATTGASC
Db	901 TGCGATGCCAACGGAGAGACACACTCAGTAACTGACAAATGGCCAAGCGAAATATTGASC	1140	901 TGCGATGCCAACGGAGAGACACACTCAGTAACTGACAAATGGCCAAGCGAAATATTGASC
Db	1021 TCGAACCCAGGTTCTCACAAACACAAACAGCCCTGCGACCGCTTCCAGGTTCTGCTCC	1260	1021 TCGAACCCAGGTTCTCACAAACACAAACAGCCCTGCGACCGCTTCCAGGTTCTGCTCC
Db	1261 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC	1080	1261 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC
Db	1081 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC	1200	1081 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC
Db	1081 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC	1320	1081 TACTCAAATGGCTCAGACTGACCGCTTCCAGGTTCTGCTCC
Db	1321 GAATCAAATGGGACACCGCTGCCAACAACTGGAAAGGACCTTCAGTGGGATC	1140	1321 GAATCAAATGGGACACCGCTGCCAACAACTGGAAAGGACCTTCAGTGGGATC
Db	1141 GAATCAAATGGGACACCGCTGCCAACAACTGGAAAGGACCTTCAGTGGGATC	1380	1141 GAATCAAATGGGACACCGCTGCCAACAACTGGAAAGGACCTTCAGTGGGATC
Db	1381 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC	1200	1381 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC
Db	1201 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC	1440	1201 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC
Db	1441 GTCTGAGCTCGAGCAATGACTTCATGATTCATCTGCTGTTGGAGCTTCACT	1260	1441 GTCTGAGCTCGAGCAATGACTTCATGATTCATCTGCTGTTGGAGCTTCACT
Db	1261 GTCTGAGCTCGAGCAATGACTTCATGATTCATCTGCTGTTGGAGCTTCACT	1500	1261 GTCTGAGCTCGAGCAATGACTTCATGATTCATCTGCTGTTGGAGCTTCACT
Db	1501 CGCAGCTCGGTGATGCCAGCACAGAGATAAGAGGGGCCAGAATCTGGCTT	1320	1501 CGCAGCTCGGTGATGCCAGCACAGAGATAAGAGGGGCCAGAATCTGGCTT
Db	1321 CGCAGCTCGGTGATGCCAGCACAGAGATAAGAGGGGCCAGAATCTGGCTT	1560	1321 CGCAGCTCGGTGATGCCAGCACAGAGATAAGAGGGGCCAGAATCTGGCTT
Db	1561 GAGACCTCGTCGTGACTCTGAGCTGAAAGTCTCAAGGAGCTTCACT	1380	1561 GAGACCTCGTCGTGACTCTGAGCTGAAAGTCTCAAGGAGCTTCACT
Db	1381 GAGACCTCGTCGTGACTCTGAGCTGAAAGTCTCAAGGAGCTTCACT	1680	1381 GAGACCTCGTCGTGACTCTGAGCTGAAAGTCTCAAGGAGCTTCACT
Db	1681 AACACTTCCGTTGGAGACCTGGAAAGTCTCAAGGAGCTTCACT	1440	1681 AACACTTCCGTTGGAGACCTGGAAAGTCTCAAGGAGCTTCACT
Db	1441 AACACTTCCGTTGGAGACCTGGAAAGTCTCAAGGAGCTTCACT	1500	1441 AACACTTCCGTTGGAGACCTGGAAAGTCTCAAGGAGCTTCACT
Db	1501 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC	1620	1501 AACCTCGAGTACAGGGCATGACGGCTTCCCGTCCGGAGGTTCTGCTCC
Db	1621 GAGGAGAACACTTCCACTCTGTTGGAGCTGAGCTTCCAGGACTCTG	2400	1621 GAGGAGAACACTTCCACTCTGTTGGAGCTGAGCTTCCAGGACTCTG
Db	2401 GAGGAGAACACTTCCACTCTGTTGGAGCTGAGCTTCCAGGACTCTG	2640	2401 GAGGAGAACACTTCCACTCTGTTGGAGCTGAGCTTCCAGGACTCTG
Db	2641 GCTGACTTACATGCTGAGCTGAGCTGAGCTGAGCTTCCAGGACTCTG	2460	2641 GCTGACTTACATGCTGAGCTGAGCTGAGCTGAGCTTCCAGGACTCTG
Db	2461 GCTGACTTACATGCTGAGCTGAGCTGAGCTTCCAGGACTCTG	2700	2461 GCTGACTTACATGCTGAGCTGAGCTGAGCTTCCAGGACTCTG
Db	2701 TGGGAGACCCAGGAGCTGAGCTTCCAGGACTCTGAGGACTCTG	2520	2701 TGGGAGACCCAGGAGCTGAGCTTCCAGGACTCTGAGGACTCTG
Db	2521 TGGGAGACCCAGGAGCTGAGCTTCCAGGACTCTGAGGACTCTG	2760	2521 TGGGAGACCCAGGAGCTGAGCTTCCAGGACTCTGAGGACTCTG

QY	2761	TGCGRAACCATACTAGATTCTGGCCTGAAGTG	2790	Db	194	CTCTCTGCCACCCAGTGTGACCAATTACTCGAGAAAGGTCTCTCCGTAAAG	253
Db	2581	TGCAGAACCCATAGATTCTGGCTGAAAGTG	2610	QY	1034	TCCGCCAGCTTCACAGACAAGATTATTCTACACACACCGCCTGGATGCCAAG	1093
XX				Db	254	TGCGCCACAGTGTGACAGACAAGATTATTCTACACACACGCCCTGGATGCCAAG	313
RC				QY	1154	GGCACGAGTGAACCTGCCCTGGGTGAGACCCACTGCCAACCCAGGT	1213
XX				DT	08-MAY-2001	( first entry)	
XX				XX		Human TR13 receptor coding sequence SEQ ID NO: 1.	
DE				XX		Human; tumour necrosis factor receptor; TR13; Trt4; infection; cancer; autoimmune disease; allergy; inflammatory disease; graft rejection; apoptosis; cardiovascular disease; aneurysm; ds. Homo sapiens.	
KW				OS			
KW				XX		WO200105834-A1.	
XX				PD	25-JAN-2001.		
PF				PF	14-JUL-2000;	2000WO-US19343.	
XX				PR	16-JUL-1999;	99US-0144087.	
PR				PR	18-AUG-1999;	99US-0149450.	
PR				PR	20-AUG-1999;	99US-0149112.	
PR				PR	10-SEP-1999;	99US-0153089.	
PA				XX		(HUMA-) HUMAN GENOME SCI INC.	
PA				PI	Ruben SM,	Ni J,	Young PE;
XX				XX		WPI;	2001-112682/12.
DR				DR		P-PSDB;	AAB35328.
XX				XX		Nucleic acids encoding 2 human tumor necrosis factor receptor polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis and treatment of, e.g. cancers, acquired immune deficiency syndrome and hypohidrotic ectodermal dysplasia.	
PR				PR		Claim 2;	Page 366-369; 418pp; English.
PS				PS		The present invention provides the protein and coding sequences of the human tumour necrosis factor receptors TR13 and TR14. These sequences are useful in the diagnosis and treatment of many diseases, including cancer, autoimmune diseases, cardiovascular disorders, allergies, neurodegenerative diseases, graft rejection, inflammation, aneurysms and infections.	
SQ		Sequence 2554 BP, 642 A; 722 C; 588 G; 602 T; 0 other;		QY	1514	TGGCAGACAGAGATAAGAGGTGGCAGATCACATTGCTGTTGAGACCTCTG	1573
Query Match		75.8%; Score 2527.4;	DB 22; Length 2554;	Db	554	GGACACGGCTGCCACAACTGGCAGCGTCTCGAGGATCACTTCAGACTACA	613
Best Local Similarity		99.9%;	Pred. No. 0;	QY	1514	TGCTGAACTCTGGCTGAGCTCTACAGTCAGCTGCTGAGGAGCTGCTG	1453
Matches	2559;	Conservative	0;	Db	314	AGGCATGCAAGCTGGAGGTGGCTGCTGAGCAGATTCACAGCTGCTGAGG	373
QY	794	CCACAGGCTTCACCTGGCCTCCAGAGGACCACTTTTCATGAGGCAAGGAGTCA	853	Db	614	AGGCATGCAAGCTGGAGGTGGCTGCTGAGCAGATTCACAGCTGCTGAGG	673
Db	15	CCGAGCTCTCACTGAGGACCAACTTCCAGAGGACCACTTTTCATGAGGCAAGGAGTCA	74	QY	1454	ACATATGACTCTAGATCTACTCTGTTGTCGAGCATAGACCTCCGAGCTG	1513
QY	854	TACAGGGCTGCTCTACTCTGAGGACCAACTTCCAGAGGACCACTTTTCATGAGGCAAGGAGTCA	913	Db	674	ACATGACTCTCATGATCTACTCTGTTGTCGAGATTAAGCTCCGAGTCTG	733
Db	75	TACAGGGCTGCTCTACTCTGAGGACCAACTTCCAGAGGACCACTTTTCATGAGGCAAGGAGTCA	134	QY	1514	TGGCAGACAGAGATAAGAGGTGGCAGATCACATTGCTGTTGAGACCTCTG	1393
QY	914	AGCAGGGCTCTCTTCCAGCAACTTCTATCAATAAGGAGAA	973	Db	554	GGACACGGCTGCCACAACTGGCAGCGTCTCGAGGATCACTTCAGACTACA	613
Db	135	AGCAGGGCTCTCTTCCAGCAACTTCTGCCCCAG-CAACTCTTATCAATAAGGAGAA	193	QY	1514	TGCTGAACTCTGGCTGAGCTCTACAGTCAGCTGCTGAGGAGCTGCTG	1213
QY	974	CTTCCTGCCACACTGTGACCCAGACAACQGGACGATGTGAGACA	1033	Db	1094	CTGCTGTTACTATATGACCGAGATTCAGGACCTCTGCTG	1153
Db				Db	1094	CTGCTGTTACTATATGACCGAGATTCAGGACCTCTGCTG	1093
QY				QY	1874	CTGCTGTTACTATATGACCGAGATTCAGGACCTCTGCTG	1933
Db				QY	1874	CTGCTGTTACTATATGACCGAGATTCAGGACCTCTGCTG	1933
QY				Db	1094	CTGCTGTTACTATATGACCGAGATTCAGGACCTCTGCTG	1093
Db				QY	1934	TTCGAAAGCCACCCGCTATGGTGTAGGCTCTGCTGCTGCTGCTG	1993
QY				Db	1154	TTCGAAAGCCACCCGCTATGGTGTAGGCTCTGCTGCTGCTGCTG	1213
Db				QY	1994	AGACACAGATCACTCTGCTGCTAATGATGCTGCACTCTGCTG	2053
QY				Db	1214	AGAACACAGATCCACTCTGCTGCTAATGATGCTGCACTCTGCTG	1273
Db				QY	2054	CCGAGCTTCACTCACTCTGCTGCTGCTGCTGCTGCTG	2113
QY				Db	1274	CCGAGCTTCACTCACTCTGCTGCTGCTGCTGCTGCTG	1333

QY	2114	CAAGCTTCACCCCAAAAGGGTGAATACTTCATCACTTAACCCCTCAGTCCTCGGAA
Db	1334	CAAGCTTCACCTCCAAAGGGTTGAATACTTCATCACTTAACCCCTCAGTCCTCGGAA
QY	2174	ACCAGGTAGAAAGTCTGTGTCACCGCAATGTCACGCCACTCGATTCCTGAGG
Db	1394	ACCAGGTAGAAATGTCACGCCACTCGACGAACTGTCACCTCGGAG
QY	2234	GTAGCTCAGGGTCTCCAACATCTATCACAGCCTACAGCTCTGCCAGGATCATCCCC
Db	1454	GTAGCTCAGGGTCTCCAACATCTATCACAGCCTACAGCTCTGCCAGGATCATCCCC
QY	2294	CAGAGGTAGAAGCTACAAGGCCGGGTTCTCACAGCCTGTCAGCCTCTGTGACG
Db	1514	CAGAGGTAGAAGCTACAAGGCCGGGTTCTCACAGCCTGTCAGCCTCTGTGACG
QY	2354	TATGGGGGACAACAGATACTGATGGATCACTCCCGCAGTGACTTTCC
QY	2354	TATGGGGGACAACAGATACTGATGGATCACTCCCGCAGTGACTTTCC
Db	1574	TTATGGGGACAACAGATACTGATGGATCACTCCCGCAGTGACTTTCC
QY	2414	ACCTGGAGTCCTGGAAATCCGGACGGTGTCTCTTTAGGCTCAAATGATGACCC
Db	1634	ACCTGGAGTCCTGGAAATCCGGACGGTGTCTCTTTAGGCTCAAATGATGACCC
QY	2474	AGTCTGCACTTCGGAGAACCACTCCGGTCAGGTGCAACAGAAACTG
Db	1694	AGTCTGCACTTCGGAGAACCACTCCGGTCAGGTGCAACAGAAACTG
QY	2534	TCCCTGGAGATTCTGGCAAGACGGTGTCTCTCTAGGGTCAACT
Db	1754	TCCCTGGAGATTCTGGCAAGACGGTGTCTCTCTAGGGTCAACT
QY	2594	TCCACTTCCTGTGGAGACGGCGCCCTGCCTGCGCTCTGCTCAGTGACCT
Db	1814	TCCACTTCCTGTGGAGACGGCGCCCTGCCTGCGCTCTGCTCAGTGACCT
QY	2654	CTAATGTCAGCAGCTGTGTGCTGGAGACGGCGCCCTGCCTGCGCTCTGCTCAGTGACCT
Db	1874	CTAATGTCAGCAGCTGTGTGCTGGAGACGGCGCCCTGCCTGCGCTCTGCTCAGTGACCT
QY	2714	AAGCTATGCTCTGGCATTCCTGCTGGAGAGACTTACCATCTGGGAAACATG
Db	1934	AAGCTATGCTCTGGCATTCCTGCTGGGAAAGTGGCACTCTGGGAAACATG
QY	2774	ATTTCGCTGAAGTGGCATTCCTGCTGGAGAGACTTACCATCTGGGAAACATG
Db	1994	ATTTCGCTGAAGTGGCATTCCTGCTGGGAAAGTGGCACTCTGGGAAACATG
QY	2834	TGACCTCTACTTTGAAAGAATCAAACCTAGATGACTACAGTCACTCCAACTGGTA
Db	2054	TGACCTCTACTTTGAAAGAATCAAACCTAGATGACTACAGTCACTCCAACTGGTA
QY	2894	TGATCTCTACTCTCAAGGACTCTGACTCTGCTGCCAGCAGCTGACAGTCTGGTA
Db	2114	TGATCTCTACTCTCAAGGACTCTGACTCTGCTGCCAGCAGCTGACAGTCTGGTA
QY	2954	AGGAGGCCAGACATGAGGACTCTACCTTACAGCAGAACTCTTGGGAGATCA
Db	2174	AGGAGGCCAGACATGAGGACTCTACCTTACAGCAGAACTCTTGGGAGATCA
QY	3014	ATCATTTACCCCAAGAGGACTCTGATGGTTGACTCTACGCACTCCACCTTG
Db	2234	ATCATTTACCCCAAGAGGACTCTGATGGTTGACTCTACGCACTCCACCTTG
QY	3074	AGGAGGCCAGACATGAGGACTCTACCTTACAGCAGAACTCTTGGGAGATCA
Db	2294	AGGAGGCCAGACATGAGGACTCTACCTTACAGCAGAACTCTTGGGAGATCA
QY	3134	CATAGGACCTTGTGCAAGCCCTGGGATTTGGTGCACATTCCTGCACCCACTGCT
Db	2354	CATAGGACCTTGTGCAAGCCCTGGGATTTGGTGCACATTCCTGCACCCACTGCT

QY	3194	GGAATCTCTCATGGCCTTATCAGATGTTGAATTAGATCTTTTATAGT	3253
Db	2414	GGAATCTCTCATGGCCTTATCAGATGTTGAATTAGATCTTTTATAGT	2473
QY	3254	ACCCAAACGCCCTTCGCTTGCCCTCAACACTGCCAATAACCCACACTTGTGTA	3313
Db	2474	ACCCAAACGCCCTTCGCTTGCCCTCAACCTGCCAATATACCCACACTTGTGTA	2533
QY	3314	AATPAAAAAAAGAAAAAAA 3334	
Db	2534	AATTAAGAAAAAAAGAAA 2554	

**RESULT** 8  
 ARZ41991  
 ID AAZ41991 standard; cDNA; 1717 BP.  
 XX  
 AC AAZ41991;  
 XX  
 DT 31-JAN-2000 (first entry)  
 XX  
 DE Human endometrium tumour cDNA derived EST 11.  
 XX  
 KW Endometrium; human; tumour; cancer; anticancer; cytostatic; EST:  
 XX

XX treatment; uterine; gene therapy; expressed sequence tag; ss.  
 XX OS  
 XX Homo sapiens.  
 XX DE19817948-A1.  
 XX PD  
 XX 21-OCT-1999.  
 XX PF  
 XX 17-APR-1998; 98DE-1017948.  
 XX PR  
 XX 17-APR-1998; 98DE-1017948.  
 XX PA  
 (META-) METAGEN GES GENOMFORSCHUNG MBH.  
 XX Rosenthal A, Specht T, Hinzmam B, Schmitt A, Pilarsky C, Dahl E;  
 XX WO1; 1999-591957/51.  
 XX DR P-PSDB; AAY59971, AAY59972, AAY59973.  
 XX PT New nucleic acid sequences expressed in uterine cancer tissues, and  
 XX derived polypeptides, for treatment of uterine and endometrial cancer  
 XX and identification of therapeutic agents -  
 XX PS  
 XX Claim 3; Page 172; 444pp; German.

This invention describes novel human nucleic acid (cDNA) sequences (A), that are highly expressed in uterine tumour tissue and which have anticancer and cytostatic activity. (A) are used (i) for recombinant expression of polypeptides (B) and (ii) to isolate complete genes. (B) are used (i) to identify agents suitable for treatment of uterine or endometrial cancer; (ii) directly for treating these forms of cancer (including expression from gene therapy vectors) and (iii) for generation of specific antibodies. (A) are identified by assembling ESTs (expressed sequence tags) from a particular tissue type before comparison of expression patterns. This allows a significantly longer fragment of the gene to be revealed, so should reduce the number of failures associated with the fact that ESTs from different libraries may represent different parts of the same unknown gene, distorting the estimated frequency of occurrence in a particular tissue. AAZ21981-242121 represents EST fragments derived from a human endometrium tumour cDNA library which encode the protein sequences represented in AAY59941-Y60328.

Sequence 1717 BP; 416 A; 492 C; 388 G; 421 T; 0 other;



PI	Schlegel R, Endege WO, Monahan JE;
DR	GGAAGTACACCAAATGACGTGCCCCAAGATCTACTCCATCAATGTCACCAATGTTATGATG 662
XX	GGTGCCTCTACTGCCGTCGCCCTAGAGGCCCTGCGCTCTGATGTCGCTCCTCCRGCA 1864
PT	Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer
PT	The invention relates to an isolated nucleic acid molecule (1) comprising a nucleotide sequence given in Tables 1-9 (AB00010-AB062213) of the specification or its complement. (1) is useful for:
PS	(a) assessing whether a patient is afflicted with prostate cancer;
PS	(b) monitoring the progression of prostate cancer in a patient;
PS	(c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;
PS	(d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;
PS	(e) selecting a composition for inhibiting prostate cancer in a patient;
PS	(f) assessing the prostate cell carcinogenic potential of a compound;
PS	(g) determining whether prostate cancer has metastasized in a patient;
PS	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;
PS	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.
SQ	Sequence 1299 BP; 321 A; 373 C; 308 G; 294 T; 3 other;
Query Match	35.2%; Score 1172.8; DB 23; Length 1299;
Best Local Similarity	99.8%; Pred. No.: 0;
Matches	1174; Conservative: 0; Mismatches: 2; Indels: 0; Gaps: 0;
QY	1145 ACCTTGAGGGGCASTGAACTGCGCTCTGGTGTGAAGACCCACTGCCAACCTSGA 1204
QY	
Db	3 ACTTGAGGGGCGTGAAGCTGCTGCGCTCTGGTGTGAAGACCCACTGCCAACCTSGA 62
QY	1205 ACCCAGCTCTTCATAACCAACACAGCACCTGCGAGCCCTGCCATATGGTCTACT 1264
Db	63 ACCCAGCTCTTCATAACCAACACAGCACCTGCGAGCCCTGCCATATGGTCTACT 122
QY	1265 CCAATGCTCAGACTGTACCGCTGCCCTCAGGACTGACCTCTGGGATTGAAT 1324
Db	123 CCAATGCTCAGACTGTACCGCTGCCCTCAGGACTGACCTCTGGGATTGAAT 182
QY	1325 ACAATGGTCAACACGGCTCCACAACTATGAAACGACGCGTCTCAGGGATACT 1384
Db	183 ACAATGGTCAACACGGCTCCACAACTATGAAACGACGCGTCTCAGGGATACT 242
QY	1385 TCGAGTACAGGGCATGACGGCTGGGGGGCTGGTGTGAATCACATTACACGCTGTG 1444
Db	243 TCGAGTACAGGGCATGACGGCTGGGGGGCTGGTGTGAATCACATTACACGCTGTG 302
QY	1445 GAGCCCTAGAACATGACTTAATGATCTCTACTCTGCTGCTGCTGCTGCTG 1504
Db	303 GAGCCCTAGAACATGACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 362
QY	1505 AGTCGCTGAGGGACAGACAGATAAAGAGGTGGCCAGAACATGCTTGTGAGA 1564
Db	363 AGTCGCTGAGGGACAGACAGATAAAGAGGTGGCCAGAACATGCTTGTGAGA 422
QY	1565 CCCCTGTTCTGACTCTACTCATGGTGGGGTGAATCTAGGACCAACA 1624
Db	423 CCCCTGTTCTGACTCTACTCATGGTGGGGTGAATCTAGGACCAACA 482
QY	1625 CTCCCTGGAGACGGTGAAGGTGCAARAGAACAGCTATACCTACATCATGG 1684
Db	483 CTCCCTGGAGACGGTGAAGGTGCAARAGAACAGCTATACCTACATCATGG 542
QY	1685 AGAACACTACCAAGCAGTGTGCAAGATCTACTCCATGAATGTCACCATGTTATGATG 1744
Db	543 AGAACACTACCAAGCAGTGTGCAACCTTGTGGCTTCAGAGGACACTTTCATGAGGCAAGCA 602
QY	1745 GGAATACACCAAGCAGTGTGCAAGATCTACTCCATGAATGTCACCATGTTATGATG 1804
Db	603 GGAAGTACACCAAATGACGTGCCCCAAGATCTACTCCATCAATGTCACCAATGTTATGATG 662
QY	1805 GCGTGCCTCTACTGCCGTCGCCCTAGAGGCCCTGCGCTCTGATGTCGCTCCTCCRGCA 1864
Db	663 GCGTGCCTCTACTGCCGTCGCCCTAGAGGCCCTGCGCTCTGATGTCGCTCCTCCRGCA 722
CC	CTAACACAATCTGAAAGCCACCCAGCTATGGTGTGTCAGGCTGTGGCTCTCCRGCA 1924
CC	CCTCTGTCCTGCTGTTACTATATGACCGAGATTAGCGA 782
Db	723 CTAACACAATCTGAAAGCCACCCAGCTATGGTGTGTCAGGCTGTGGCTCTCCRGCA 782
QY	1865 CCTCTGTCCTGCTGCTGTTACTATGGTGTGTCAGGCTGTGGCTCTCCRGCA 1984
Db	783 CTAACACAATCTGAAAGCCACCCAGCTATGGTGTGTCAGGCTGTGGCTCTCCRGCA 842
QY	1985 CAGGGACCAAGAACAGATACTCCACTCTGNGCTCAATGATGTTGACCTCTCAGGCA 2044
Db	903 ACACCTCAACCAGGACTTCACTACACTTCAGCCGTTGGCAACACCGTOACTCTTG 962
QY	2105 CTGGAGGCCAAGCTTCACTCCAAAGGGTGAATACTTCATCAGTTACCTGAGTC 2164
Db	963 CTGGAGGCCAAGCTTCACTCCAAAGGGTGAATACTTCATCAGTTACCTGAGTC 1022
QY	2165 TCTGTGGAACACAGGGTAGGAAATGTCGTCGTCGACGACATGTCACTGACCTCGGA 2224
Db	1023 TCTGTGGAACACAGGGTAGGAAATGTCGTCGTCGACGACATGTCACTGACCTCGGA 1082
QY	2225 TTCTGTGAGGTGACTCAGGTTCTCAAACTCATCACAGCCCTACGGTGTGCCAGGAGTC 2284
Db	1083 TTCTGTGAGGTGACTCAGGTTCTCAAACTCATCACAGCCCTACGGTGTGCCAGGAGTC 1142
QY	2285 TCATCCCCCAGGGTACAGGCTACAGGGCTACAGGCCGG 2320
Db	1143 TCATCCCCCAGGGTACAGGCTACAGGCCGG 1178
RESULT	10
ID	ABV2891
XX	ABV28991 standard; cDNA; 1299 BP.
AC	ABV28991;
XX	
DT	16-SEP-2002 (first entry)
XX	
DE	Human prostate expression marker cDNA 28992.
XX	
KW	Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker; gene; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO2001060860-A2.
XX	
PD	23-AUG-2001.
XX	
PF	20-FEB-2001; 2001WO-US05171.
XX	
PR	17-FEB-2000; 2000US-183319P.
PR	16-MAR-2000; 2000US-189862P.
PR	16-MAY-2000; 2000US-207454P.
PR	09-JUN-2000; 2000US-211314P.
PR	18-JUL-2000; 2000US-219007P.
PR	13-DEC-2000; 2000US-255281P.
XX	
PA	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX	
PT	Schlegel R, Endege WO, Monahan JE;
XX	
DR	WPI; 2001-662795/76.

XX  
 PT Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer  
 PT  
 XX  
 PS Claim 1; Page 6131; 11750pp; English.

XX  
 CC The invention relates to an isolated nucleic acid molecule (I) comprising a nucleotide sequence given in Tables 1-9 (ABV0010 ABV62213) of the specification or its complement. (I) is useful for:  
 CC (a) assessing whether a patient is afflicted with prostate cancer;  
 CC (b) monitoring the progression of prostate cancer in a patient;  
 CC (c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;  
 CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;  
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
 CC (f) assessing the prostate cell carcinogenic potential of a compound;  
 CC (g) determining whether prostate cancer has metastasized in a patient;  
 CC (h) assessing the aggressiveness or indolence of prostate cancer in a patient;  
 CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.  
 XX  
 Sequence 1299 BP; 321 A; 373 C; 308 G; 294 T; 3 other;

Query Match Similarity 35.2%; Score 1172.8; DB 23; Length 1299;  
 Best Local Similarity 99.8%; Pred. No. 0;  
 Matches 1174; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 ACTTGAGGGGCACTGAACCTGCCTGCCCTGGTGAAGAACCCACTGCCACCCCTCA 1204  
 Db 3 ACTTGAGGGGCACTGAACCTGCCTGCCCTGGTGAAGAACCCACTGCCACCCCTCA 62

QY 1205 ACCCAGGTCTTCACACACACAGCACCTGCCAGCCCTGCCATATGGTCTACT 1264  
 Db 63 ACCCAGGTCTTCACACACACAGCACCTGCCAGCCATGGTCTACT 122

QY 1265 CCAATGGCTCAGACTGACCGCTGCCCTGCCAGGGACTGACCTGCTGGGATTGAT 1324  
 Db 123 CCAATGGCTCAGACTGACCGCTGCCCTGCCAGGGACTGACCTGCTGGGATTGAT 1812

QY 1325 ACAATGGTGCAGACACGGCTGCCACAAACATGGAAACGACCGCTCTCACTGGATCACT 1384  
 Db 183 ACAATGGTGCAGACACGGCTGCCACAAACATGGAAACGACCGCTCTCACTGGATCACT 242

QY 1385 TCGAGTACAAGGCATGACAGGCTGGGAGSTGGTGTGGTGTCACT 1444  
 Db 243 TCGAGTACAAGGCATGACAGGCTGGGAGSTGGTGTGGTGTCACT 302

QY 1445 GAGCCCTCAGACATGACTGATGATCTCACTCTGGTGTGCCAGGATTAGCCTCCG 1504  
 Db 303 GAGCCCTCAGACATGACTGATGATCTCACTCTGGTGTGCCAGGATTAGCCTCCG 352

QY 1505 AGTCGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 1564  
 Db 363 AGTCGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 422

QY 1565 CCTCTGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 1624  
 Db 423 CCTCTGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 482

QY 1625 CCTCTGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 1684  
 Db 483 CCTCTGGTGTGGACAGACAGAGAATAAGAGGTTGGCTGCCAGAAATCATTTGTCTTGAGA 542

QY 1685 AGAACACTACAGAGGCTTACCTGGCCCTCCAGAGGACCACTTCACTGAGGAAAGCA 1744  
 Db 543 AGAACACTACAGAGGCTTACCTGGCCCTCCAGAGGACCACTTCACTGAGGAAAGCA 602

QY 1745 GAGAGTACACCATGAGGTGGCAAGATCTACTCCATAGTCACCAATGTATGATG 1804  
 Db 603 GAGAGTACACCATGAGGTGGCAAGATCTACTCCATAGTCACCAATGTATGATG 662

QY 1805 GGTTGGCTCTACTGCCGCCCTGGCCCTAGAACCTGTGAGTGGGCTCCCTCTGCA 1864  
 Db 663 GGTTGGCTCTACTGCCGCCCTGGCCCTAGAACCTGTGAGTGGGCTCCCTCTGCA 722  
 QY 1865 CTCTGGCTCTGGTACATATGGCCAGATTCAGGACCTCCAGGACCTCCCTGGGCTCCCTCTGCA 1924  
 Db 723 CCTCTGGCTCTGGTACATATGGCCAGGACCTCCAGGACCTCCCTGGGCTCCCTCTGCA 782

QY 1925 CTAAACAAATCTGAAAGCCACCAACGCTTAATGGTGTGCCAGGCCCTGGTGTGGTC 1984  
 Db 783 CTAAACAAATCTGAAAGCCACCAACGCTTAATGGTGTGCCAGGCCCTGGTGTGGTC 842

QY 1985 CAGGGACCAAGACACAGATCCACCTCTGCTCACATGATGACCTTCACGCA 2044  
 Db 843 CAGGGACCAAGACACAGATCCACCTCTGCTCACATGATGACCTTCACGCA 902

QY 2045 ACATCCACACAGACTTCAACTACACACTCTCCGTTGGCAAAACACGGTACTCTG 2104  
 Db 903 ACATCCACACAGACTTCAACTACACACTCTCCGTTGGCAAAACACGGTACTCTG 962

QY 2105 CTGGAGGCCAACGACTTCACCTCCAAGGGTGAATACTCCATCACTTACCCCTAGTC 2164  
 Db 963 CTGGAGGCCAACGACTTCACCTCCAAGGGTGAATACTCCATCACTTACCCCTAGTC 1022

QY 2165 TCTGTGGAAACAGGGTAGGAAATGCTGTGTCACCGACATGTCACCTGCCGGA 2224  
 Db 1023 TCTGTGGAAACAGGGTAGGAAATGCTGTGTCACCGACATGTCACCTGCCGGA 1082

QY 2225 TCTGTGGAGGTGACTGAGGTCTCCAAATCTACAGCCCTACGCTCTGCGAGGTCA 2284  
 Db 1083 TCTGTGGAGGTGACTGAGGTCTCCAAATCTACAGCCCTACGCTCTGCGAGGTCA 1142

QY 2285 TCATCCCCCAGAGGTGACAGGCTACAGGGGG 2320  
 Db 1143 TCATCCCCCAGAGGTGACAGGCTACAGGGGG 1178

RESULT 11  
 AAF8977 ID AAF8977 standard; DNA; 1149 BP.  
 XX  
 AC AAF8977;  
 XX DT 23-JUL-2001 (first entry)  
 XX DE Nucleotide sequence of a human protein expressed in tumour cells.  
 XX KW Tumour cell; immunological disease; autoimmune disease; cancer;  
 XX infection; ss.  
 OS Homo sapiens.  
 XX FH  
 Key CDS Location/Qualifiers  
 FT 1..1149 /\*tag= a  
 FT /product= "tumour expressed protein"  
 XX PN WO20131003-A1.  
 XX PD 03-MAY-2001.  
 XX PF 30-OCT-2000; 2000WO-FR03032.  
 XX PR 29-OCT-1999; 99FR-0013629.  
 XX PA (FABR ) FABRE MEDICAMENT SA PIERRE.  
 XX PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;  
 XX DR WPI; 2001-328651/34.  
 DR P-PSDB; AAB83853.  
 XX New nucleic acid, expressed in tumours and lymphoid tissue is useful for

QY	1183	AAGACCCATCGCCCAACCCTGCAACCCAGCCTCTTCACAAACCAACAGCACCTGCCAG	1242
Db	721	AAGACCCATCGCCCAACCCTGCAACCCAGCCTCTTCACAAACCAACAGCACCTGCCAG	780
QY	1243	CCCTGGCCATATGGTCTCTACTCCATGTCTCAGACTGAGATGACCGCTGCTGGCTGGCTGGAGCT	1302
Db	781	CCCTGGCCATATGGTCTCTACTCCATGTCTCAGACTGAGATGACCGCTGCTGGCTGGAGCT	840
Qy	1303	GAACCTGCTGGATTGATCAATGTTGGACACCCCTGCCACACATGGAACAG	1362
Db	841	GAACCTGCTGGATTGATCAATGTTGGACACCCCTGCCACACATGGAACAG	900
QY	1363	ACCGITCTAGTGGATCACTTGAGTCAAGGGCATAGACAGSGCTGGAGGTGGCTGTT	1422
Db	901	ACCGITCTAGTGGATCACTTGAGTCAAGGGCATAGACAGSGCTGGAGGTGGCTGTT	960
QY	1423	GATGACATTTACAGAGCTCTGGACCTGAGACATGATGTCATGATCTCATCTGTT	1482
Db	961	GATGACATTTACAGAGCTCTGGACCTGAGACATGATGTCATGATCTCATCTGTT	1020
QY	1483	GTGCCAGGTTAGACCTGCCAGCTGGTGTGCCAGACAGAATAAGGGTGGCC	1542
Db	1021	GTGCCAGGTTAGACCTGCCAGCTGGTGTGCCAGACAGAATAAGGGTGGCC	1080
QY	1543	AGATCACATTGCTGCTTGAGACOCCTGTTCTGTAACCTGTCAGCTACTCTCATGTT	1602
Db	1081	AGAACACTTGTCTTGAGACCCCTCTCTGAACTGTCAGCTACTCTCATGTT	1140
QY	1603	GGTGTGAAAT 1611	
Db	1141	GGTGTGAAAT 1149	
RESULT 12			
AAH76195			
ID	AAH76195	standard; cDNA; 1587 BP.	
XX			
AC	AAH76195;		
XX			
DT	29-OCT-2001	(first entry)	
DE			
DE		Human seven-transmembrane protein 50288 cDNA sequence.	
XX			
KW		seven-transmembrane protein; G-protein coupled receptor; GPCR; human;	
KW		17724; 50288; 31945; antiinflammatory; antiulcer; cytostatic; virucide;	
KW		hepatotrophic; immunosuppressive; gynecological; neuroprotective;	
KW		anti-HIV; immunostimulant; dermatological; antiatherosclerotic; cardiotonic;	
KW		antiarrhythmic; antiParkinsonian; nephrotoprotective; antithyroid; hemostatic;	
KW		cerebroprotective; osteopathic; analgesic; gene therapy; nootropic; ss;	
XX			
OS		Homo sapiens.	
XX			
FH	Key	Location/Qualifiers	
FT	CDS	308..1427	
FT			
FT		/product= "50288 protein"	
XX			
PN	WO200159117-A2.		
XX			
PD	16-AUG-2001.		
XX			
PF	12-FEB-2001; 2001WO-US04536.		
XX			
PR	11-FEB-2000; 2000US-0182061.		
XX			
PA	(MILL-) MILLENIUM PHARM INC.		
XX			
PI	Glucksmann MA, Silos-Santiago I;		
XX			
DR	WPT; 2001-514670/56.		
DR	P-PSDB; AAB85768.		
XX			
New seven-transmembrane protein/G-protein coupled receptor polypeptides			



Best local Similarity	Conservative	60.5%	Pred.	No.	8 2e-273;	Mismatches	116;	Indels	28;	Gaps	8;
Matches	1755;										
Db	1188	CAACCTGAGTTATACAAAGTACATCTCTTGCCATCCCTGTCCTGAGAACATT	1247	Qy	1263	CTCCAATGTC--AGRCTGTTACCGGCTGGCCTGCGAGGACTGAACCTGTTGGATT	1319				
b	192	GCTTCACGCCCTCAAAGAGTCTCTAGTACCATGACAGCGGCTGAGACGGG	251	Db	1248	TTAGATGAGAACAAAGATGTAGACCATGTCAGCAGGAGCTGACTGGCTT	1307				
b	171	GCTTCCTCTCTCCAGGAGAAGATTACACTTGTAAATACCGAATGTAGACGG	230	Qy	1320	TGATACAAATGGAAACACCTGCCCCAACACAGGAAACGACCTCTCAGGGAT	1379				
b	252	TTCCAGGAGGAGGCTGGCTGGCATACCCGGCTGAGGCTACAGGCTGGACC	311	Db	1308	TAATATAATGGAAATGTCAGTGCCTTCGGCACATGAAATAAAGAA	1367				
b	231	CTCCAGGGAGGAGAAGTGTGCAATTCCTCAGTGACTCTCTGTCGCTGACCC	290	Qy	1380	CAACTCGGACAAAGGCTGACAGGGCTGGAGTGGCTGATCACATTACAGC	1439				
b	312	CCTCAAGGGCACCGAGTCTCTCTGCACGGGGGGTGGAGGATGAGGA	371	Db	1368	GAATCAAGTGGATGATGGAGATCTGAGGATATGAAATGAGAA	1427				
b	291	ATGAGGAGCAAGAACTTCTCTGCTCTGGAGGATCTGAGAATGAGAA	350	Qy	1440	TCTGGAGGCTGAGACATGACTCTGATTCCTACTCTGGTGTGCGCAGATTGAC	1499				
b	372	CGAGTCAGTAGAACCCATGCGCTGAGGCGCTACTCCCTGCACAGCGATCGGTG	431	Db	1428	GGCTGGAGGTCTGACATGTGTTACCTGATCTTAACCTGCAATATCCCAGGATTAAAC	1487				
b	351	CTAGGTATGCACTTAAGTGTGGAGGACCTATTCTTGCGAGTGCACAAATG	410	Qy	1500	TCCGAGCTGGGATGGATGATGGTGGAGATCTGAGTGGAGATCATCCAGATGG	1559				
b	432	TAGTGGGATGACTGCGCCAATGGCTGCGCCCTCAGGACACATGGAGCTGG	491	Db	1488	ACCAACATCTGACTGGGCCAC--GGGTCTGACTGAGTGGAGATACATTGCTT	1544				
b	411	TGATGGGATGATTGCGGCGAGATTCTACATGCCAACATTGAGGACTGTGGT	470	Qy	1560	TGAGACCTCTGCTGAGACTGTGAGCTACTATGAGTGGGGTGAATCTAGAGC	1619				
b	492	CAGTGCCTGAGTCACTGGTCCA---CGGGAACTGTGTTCTCCAGAGTGGGG	548	Db	1545	TGAGACCCCTGCTGAGTGGAGATTAAGGGGGCAGATCACATTGCTT	1604				
b	471	GCGCCCTGTGACGAGGCCAGGCCAGGGCTGTAACACTCTCTGGATCCCGTGA	530	Qy	1620	CAACACTCTGAGAGCTGAGCTCATGATTCTACTCTGGTGTGAGTAACT	1679				
b	549	CTACATGCCCTCACACGGGAGATCACGCCACACTGATGTACCCGTCACCTGA	608	Db	1605	TACAATGTGTTAGATGTGTTACCTGATCTTAACCTGCAATATCCCAGGATTAAAC	1664				
b	531	CTACATGAACTTAATGTTGAGACTGCGACGCTGCTGTTGACTATGCTGRCACCTAA	590	Qy	1680	TGAGGAGACACTACAGGAGGTTCACTGGCCCTCCAGGAGGACAT	1739				
b	609	GAATCTGGCAGCTGGTACTACTGAACTACTATCCGACGCTGACATCTGAGT	668	Db	1665	CTTCGARGATGCACTTTATGTTACATTGAGTCACTGGGATCAAGGTCAGG	1724				
b	591	GAAGTCAGGCTATGCTCTTGTGAGTACCGAGTATGAGACTC--CAGTGGTAAACT	650	Qy	1740	AAGCAGGAGACACTACAGGAGGTTCACTGGCCCTCCAGGAGGACAT	1799				
b	669	TTCGCTGAGTCACTGGTCTGAGTACCGAGTATGAGACTC--CAGTGGTAACT	650	Db	1725	TAATAGGGTTCATGATGAGATGGGAGATTCTCATGAGCCTCTGAGG	1784				
b	651	CTTATTCAAATGATGAGTGGAGATGACACCCACTGACAGTGGTAAACT	710	Qy	1800	GAATGGGCTGCTCTACTGCGCCTGCGCCCTAGAACGCAACAGCTTACAT	1859				
b	726	ACAGAGAA---AGATGGAAATCCACAGTGTGGACCTAATCGAGGAATATGCTC	782	Db	1785	TGATGGGGGGGCTCTCATGCGCGTGTGCGCTTGTGCGCTTGTGTTGACAGCAGGGTTCATC	1844				
b	711	TACAGACAACTGAGAATGGGCTCTGATTCTGTAATGCTGTAATCAGGACAACTACT	770	Qy	1860	CTGCACCTCTGCTGCTGGTTACTATATGACCCAGATCAGGACACTTCTGAGG	1919				
b	783	CTATGAGAACACACCTCTCAGATGGCCAAGTACCCAACTGCTGCTGTGGTAA	842	Db	1845	GTGTGRCCTGCCCCCTGAGCCACTACTATGAGAAGATGGGAGATTCTCATGAGCCT	1904				
b	771	CTACTGGAGAACTACAGGCACTTATGGGTCTAAGGGGTCGAAGCTGCTGGTAA	830	Qy	1920	CCGCCCTAACATAATCTGAGAACGCCACAGCCTATGGCTTCCAGGCTGTGCCCC	1979				
b	843	AAACATGCGCATAACAGGGGGGCCAACCTGAGATGCTTCCCTGCAACAACTGAC	902	Db	1905	TCCACCGACACCTACTGTGCTCATGATCAGCTTATGGCTTGGAGGGCTGTGATTCAG	1964				
b	831	AAATATCACAAATGAGGGGTGCGTACACATGAGTGTCTGAGCCAGGAC	890	Qy	1980	TGGTCAGGAGGACAGAACAAAGATCCACTCTGCTGCTACATGAGTCACCTTC	2039				
b	903	GTATGAGAACAGCAGGGCTCTCTCTGCAACCTGCCCAGCAACTTATTCAA	962	Db	1965	CGGGCTGGGGAGTAAACAACTCAGGACCATCAGGCTGTGCTTATAGTGACGCTT	2024				
b	891	ATTCAGCAACAAACACCAGGTCATCACTGCGCCAGGCTGTCAGGACAACTATCTGA	950	Qy	2040	ACGCAACACTCCACCAACGGAGGACTTCTCACTACACTCTCGCCTTGGCAACACGGTCAC	2099				
b	963	TAAGGAGAACACTCTGAGCCACAGGTTGACCTGACAAACTGAGAAGGGTCTC	1022	Db	2025	CCATGAAAGAAATCAGATTGACTGACTATGACTTGTGACCTCAGCAGTGTGGCTC	2084				
b	951	GAAGGGCCAAAGAATGATGAGGTAA - -AGAGACTCTCAATTGAGTTCAG	1007	Qy	2100	TCTGCTGAGGGCAGCTGACTCTGAGGTTGAAATACTCTCATCTTACCT	2159				
b	1023	TTCGCTGAACTCTGCGCCAGTTGCAAGACAAGATTCTACACACACGGCTC	1082	Db	2085	ATTAGTAATGAGGCTGAGGAGGCTGAGGCTGAGGCTGAGGCTGAGGCTG	2144				
b	1008	TGAGTGTACAGAGCGCCCTCTGTTACCAAAAGACTATGCTACATGCTAC	1067	Qy	2160	CAGTCCTGTTGAAACCGGGTAGGAAATGCTGCGCAGACAGTCAGCT	2219				
b	1083	CGATGCCACCGGAGACACACTCTGAGAACAAATCTGTAGCG	1142	Db	2145	CAGTTATGTGGCATGGGGAGAAGTGTGCTGCTTGTGCTTACCAAAATACAGACT	2204				
b	1068	TGATGAGAACAGGAGAACACAGAATGAGTGTGAGGAGAAGATGCTGCGCTG	1127	Qy	2220	CCGGATCTCTGGGGTGTAGCTGAGGCTGAGGCTGAGGCTGAGGCTG	2270				
b	1143	GGACCTCTGGGGGAGCTGAGACTGCTGCTGCTGCTGCTGCTGCTGCTG	1202	Db	2205	TACAGTAAGAAATGTTGCGAGGTCACTGAGTACAAATTGTTGAGGGCTT	2264				
b	1128	GGATCTCAGAGATGCTTATGAGTGTGAGGAGAAGATGCTGCGCTG	1187	Qy	2271	CTGCCAGGCGACATGCACTATGCAAGGAGGTTGCGACCCATCACA	2330				
b	1203	CAACCCAGGCTCTCAACACACACAGCCCTGCCCATATGGTCTCA	1262	Db	2265	ATGCCATGTCACAAATPATCTCTGAGGAGGTTGCGACCCATCACA	2324				



DB	361	GGATTCGTTGTAGTGGTGGGGATGCCCCATGGCTTCAGCCATCAGCCAC	420
XX		(HUMA-)	HUMAN GENOME SCI INC.
PI	Ruben SM,	Young PE,	Baker KP;
XX			
DR	WPT;	2001-138754/14.	
XX			
PT	New nucleic acid molecule encoding a TR16 tumor necrosis factor receptor polypeptide, useful for the diagnosis and treatment of cancer diseases and disorders associated with the inhibited or increased apoptosis. In particular inflammatory diseases, cancers, immune and neurodegenerative disorders may be treated.		
XX			
PS	Disclosure; Fig 1; 286pp; English.		
XX			
CC	The present invention relates to a TR16 receptor (tumour necrosis factor receptor superfamily). The invention is useful for treating diseases and disorders associated with the inhibited or increased apoptosis. In particular inflammatory diseases, cancers, immune and neurodegenerative disorders may be treated.		
CC			
CC			
SQ	Sequence 3390 BP; 979 A; 722 C; 801 G; 888 T; 0 other;		
Query	Match 27.0%; Score 901.4; DB 22; Length 3390;		
Db	Best Local Similarity 60.0%; Pred. No. 1.2e-255; Matches 1835; Conservative 0; Mismatches 1061; Indels 27; Gaps 720		
QY	778 GRCCTCTATGGAGAACAGAACAGACGCTTCAGTATGGACCAAGTGGCTG 837		
Db	721 GRCCTCTATGGAGAACAGAACAGACGCTTCAGTATGGACCAAGTGGCTG 780		
QY	838 GTGAGAAACATGCCATACAGGGTGCCCTACACTCGAGATGCTTCCC 897		
Db	781 GTGAGAAACATGCCATACAGGGTGCCCTACACTCGAGATGCTTCCC 840		
QY	898 GGACGPMGCAAGAACAGGGCTCCCTTGCAAACTTGCCAGCCACTCTP 957		
Db	841 GGACGPMGCAAGAACAGGGCTCCCTTGCAAACTTGCCAGCCACTCTP 900		
QY	958 TCAATAAGGAGAACTTCTGCCACAGTGACCTGACAATACTCAGAGAAGGA 1017		
Db	901 TCAATAAGGAGAACTTCTGCCACAGTGACCTGACAATACTCAGAGAAGGA 960		
QY	1018 TCT 1020		
Db	961 TCT 963		
RESULT	15		
AAF75054	ID AAF75054 standard; DNA; 3390 BP.		
XX			
AC	AAF75054;		
XX			
DT	10-MAY-2001 (first entry)		
XX			
DE	TR16-short receptor DNA.		
KW	TR16 receptor; tumour necrosis factor receptor superfamily; ds. apoptosis; inflammatory; cancer; immune; neurodegenerative; ds.		
XX			
OS	Unidentified.		
XX			
PN	WO200112671-A1.		
XX			
PD	22-FEB-2001.		
XX			
PF	10-AUG-2000; 2000WO-US21885.		
XX			
PR	12-AUG-1999; 99US-0148348.		
PR	13-AUG-1999; 99US-0148683.		
PR	13-AUG-1999; 99US-0148870.		
PR	16-AUG-1999; 99US-0149181.		
PR	17-AUG-1999; 99US-0149453.		
PR	18-AUG-1999; 99US-0149498.		
XX			
PA			
XX			
PI			
XX			
DR			
XX			
PT			
XX			
PS			
XX			
CC			
CC			
CC			
DB	192 GCTCACCCCTGCAAAGTCGAGTACCATATGAGTACGGTACAGGGCTGACGCCAGGG 251		
QY	312 CGTCACCCCTGCAAAGTCGAGTACCATATGAGTACGGTACAGGGCTGACGCCAGGG 371		
Db	171 GCTTCCTCTGCAGGAAAGTATACCTTGCTTCCC 371		
Db	291 AGTGAAGGCAAAGATGCACTTGCTCTGCTTGCTTCC 350		
QY	252 TTCCAGGTTGGAGGGTSCCGTSCCGTACCCGGCTGTGACCCAGCCTGCTGACCC 311		
Db	231 CTTCAGGGGGAGAGTGTGCAATTCTGAGTGGACTCTC 290		
QY	312 CGTCACCCCTGCAAAGTCGAGTACCATATGAGTACGGTACAGGGCTGACGCCAGGG 371		
Db	171 GCTTCCTCTGCAGGAAAGTATACCTTGCTTCCC 371		
Db	291 AGTGAAGGCAAAGATGCACTTGCTCTGCTTGCTTCC 350		
QY	372 CGTCATGTAAGCCATGCCCTGAGGGCCGCTACTCC 431		
Db	351 CGAGGTAGCACTGAGTGGAGGACCTATTGCGGAGATTCTACATGCCAACATTGAGCTTG 410		
QY	432 TGAGTGGATGAGCTGCCCTCAGCCACATGGACCTGTGA 491		
Db	411 TGATGGATGATTGCCGAGATTCTACATGCCAACATTGAGCTTG 470		
QY	492 CAAGTGTGCTGAGTCA---CGGGAACTGTACTTGCTCCAAAGTGGTCCCGGGCGA 548		
Db	471 GGCCCTCTGACAGCAGGCCAGAGGGCTGTAAACACTCTCTCTGATCCCTGCTG 530		
QY	549 CTACATGCCCTCAACAGGGAGAATGCCAGCACGCAACTGATGTAAGCCGTCACCTGAA 608		
Db	531 CTACATGAACTTAATGGTGTACTGACCTGACSGTGTCTTGATCTGCTGTCACCTGAA 590		
QY	609 GCAATCTGGCACCGTAACTTGGAATTAATCTGACATGCCAGCACCACTTGATGTCACCTGTT 668		
Db	591 GAGTCAGCTATGCTCTTGAGTGGACCTGATGTCACCTGTT 650		
QY	669 TTTCGTCAGAATGCCAGCTGCCAGCCAAATGCCAGATGACTC---CAGGTGTGAGAC 725		
Db	651 CTTTATTCAAAATGATGTCAGTGCAGGAGATGCCACCACTGACAGGCACTTGTT 710		
QY	726 CACAGAGA---AGGATGGAAATCCACAGTGGAGGACTTAATGCCAGCAATAATGTCCT 782		
Db	711 TACAGACATGGAGATGGCTCTCTGTAATCAGGCAACACATACT 770		
QY	783 CTTATGGAGAACGACGCTCTGAGATGCTTCCC 842		
Db	771 CTACTGGAGAACGCTCTTGGTCTAAGGGCTACGCGTCACCTGTCGTTCTG 830		
QY	843 AACATTCCTAACAGGGGGCTACACTCGAGTCTCCC 902		
Db	831 AAATACACATTGAGGGGGCTACACATCAGATGTTCTGCAAGGCCAGGCAC 890		
QY	903 GTATGGAGAACGAGAACGAGCTCTCTGCAACTTGCCAGGCCACTCTTATCAA 962		

Db	891	ATTCAGCAACAAACACCAGGTTCATCRACTGCACCGGTGTCAGAACACTTCTGA	Db	1965	CGGGCTGGAGTAACAACTAGGACCATGGTTGTCTATAGTCACITGCTTCTCA
Qy	963	TAAAGGAAACATTCTGCCAACAGCCCTAAGGTTCCAGGCCTGTGCTG 1022	Qy	2040	ACGCACACTCCACCCAGGACTTCACACTTCACACTTCACGTTTGCAACCCCTCAC
Db	951	GAAGAGCCAAAGATGTATAAGGTG 1007	Db	2025	CCATGAAAGAAATCAGATTGCACTATGACTTTCAGCAACTCTCGAGTCAGTGGCTC
Qy	1023	TTCTCTTAACCTGCSGCCACCTTGACAGACAATACTCGAGAAAGATCTC 1082	Qy	2100	TCTTGCTGGAGGGCAACCTTCACCTCAAAGGTGAAACTTCATCACTTACCT
Db	1008	TTGAGTGTACAGAGCAGCCTCTCTGTACCAAGAAAGACTTTCAGATCCATG 1067	Db	2085	ATTAATGAAATGGCCACGTTCACCTCAAGAACAAACTTCATTCAT
Qy	1083	CGATGCCAACGGAGACACACTGATGCAATTGGCAAGCGAACATCTAGGA	Qy	2160	CAGTCCTGGAACCCAGGTAGAAAATGTCGTTGACCGACATGTCACACTACCT
Db	1068	TGATGAGAAGAGACAGACAGATAATGTCAGTGGATAGAGCCAAATCTCGGGA	Db	2145	CAGTTATGGCATGAGGGAGAGATGGCTCTGACAGTAACTACAGACTT
Qy	1143	GGACCTTGAGGGGAGTGAGCTGCTGCTCTGGTGTAGAGAACCCACTGCCAACCTG	Qy	2200	CGGATTCCTGAGGTGATGCGAGGTCAAGTTCAGTGGCT 2270
Db	1128	GGATCCTCACGATGCTTATAGATGAGTCGCTTCTGGAGAGAAGGAGTGTGGCCTG	Db	2205	TACAGTAAAGAAATAGTGCAGGTCAAGTATTACACAAATTGGTAGGGCAATT
Qy	1263	CTCCATGG -- CTGAGACTTACCGCTGCCCTCGAGGACTAACCGCTGGG 1319	Qy	2271	CTGCCAGGGAGTCATCCCGCAGGGTACAGGTACAAAGCCGGTTCTCAC
Db	1248	TTCAGATGGAAACCAAAAGAATGTCAGACATGTCAGCAGGAGCTGACATGGCT	Qy	2285	ATGGCAGTCACATTATCTCTGAAAGTAAGGGTTCCAGCAGCCATTATCACA
Qy	1320	TGATACAAATGGTGGAACACGCTGCCAGAACACTGGAAACGACGGTCTCAGGGAT	Db	2331	GCCGTGTCAGCCTTCGTGAGTCAGTATTGGGAGACACAGAATGACTCTGATGGAT
Db	1368	CTGATTAATAGTGGATGTCCTTCCTGGAAACTTCAGAGTTCAGAGTGG 1367	Qy	2325	ATCCATCATCTGCGAGATACATCATAGGAGTCACAGTGTGAAACCATATA
Qy	1380	CAACTTGAGTCAAGGGCATGACAGGCTGGAGSTGGCTGGTGTGATCACATTACACG	Db	2385	TAATAAAAGAAGATATGTTCCAGTCACAGTCACAAAGCAATACAGATGTCAT
Db	1428	GCTCTGGAGGTTCTGACATGATTACTGTGACTTAACTGTCATGTTAACCC	Qy	2445	TTAGTCCTACAGGAAACATCTGTTAATGGGGATCACTGTTGTA
Qy	1500	TCCGAGCTGGTATGGCAGACAGAGAAATAAGAGGTGGCCAGAACTCATTTGCT	Db	2451	TTATAGGTCATGATGTCACCCAGTCCTGGAGTACCGGACGATGATCTCT
Db	1488	ACCAACATCTATGACTGGGACCT -- GGCTTCGAATGGAGAAATACATTGTC	Qy	2511	CAGTGGAGTCAGAACACTGTCCTGGAGAATGTCGTCAGAGTCGTCAGTCAG
Qy	1620	CAACACTCTGGAGCAGCTGGAAAGGTTCAGAACAGGCTCTATACCTACAT	Db	2505	GAGGTGATACCTACTAACATCTGGAGGAGGAGTTCAGTCAGTCAGGCCAG
Db	1605	TGAGACCTCTGTTCTGACTGAGCTGAGCTACTCATGTTGGTGAATCTTAGGC	Qy	2571	TGGACCTGTTGTCACCTTCACCTCTGTSGGAGACCGGCGCTGCTGCGCT
Qy	1680	TCAGACCCCTCTGTCAGCTGACTGTTGACTCTCATGGTGGATATATGAGAAG	Db	2565	AGGTACACTGTGATGGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTC
Db	1665	CTTCAGAAATGCAACTTACATGAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG	Qy	2691	TACTTAGGTTGGAGAACCCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG
Qy	1740	AAGCAGGAAGTACACCAATGAGTGGCCAAAGTACTCCTAATGTCACCAAGTAT	Db	2685	CTGCTCAGTGGCTACTACATCTGTCAGCTGGCTGGATCTGTCAGAGAC
Db	1725	TATAGACGGTTCATCATGAGATGGATGTTTCTACAGCCACTATGAGCT	Qy	2751	AGTCACCTCTGAAACCCATGATTCCTGCTGAGMTGGCATCTCAGGCCCTG
Qy	1800	GRATGGCGTSCCTCTACTGCCGCCCTGCCCCTAGAGCCCTGTGCTCC	Db	2745	GTTCGCAACCTGTGAAACGGTGTGACTTTCGGCTGAGGTGGAGCCGGTGGAC
Db	1785	TGATGGGGTGGTCTCATGCCGCCCTGCCCCTGCTGACAGTCGGTTCATC	Qy	2811	TACTGCCATCTGTCACCGCTCTGACCTGTCACCTTGAAAGAAATCAAACATAGA
Qy	1860	CTGCACTCTGTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	Db	2805	TACGCCCTTGTGGCTGACTCTGCTGAGGTGGAGCCGGTGGAGCTT
Db	1845	GTGTCAGCCCTGCCCTGCCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	Qy	2871	GTACAGTACTCCAAAGCTGGTGA 2893
Qy	1920	CCCCCTAACAACTCTGAAAGCCACGCCCTAAGGTTCCAGGCCTGTGCTGCTG	Db	2865	GAAGACCATTTGAACTCTGTTCA 2887
Db	1905	TCCACCTGACACTRACTGTCTCATCATGAGTCATGCTGCTGCTGCTGCTG			
Qy	1980	TGGTCCAGGACCAAGAACAAAGATCCACTCTGCTGCTGCTGCTGCTGCTG			

Search completed: March 11, 2003, 05:44:30  
Job time : 517 secs

